MCID: THR100
MIFTS: 62

Thrombocytopenic Purpura, Autoimmune

Categories: Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Thrombocytopenic Purpura, Autoimmune

MalaCards integrated aliases for Thrombocytopenic Purpura, Autoimmune:

Name: Thrombocytopenic Purpura, Autoimmune 57 76 59 13
Idiopathic Thrombocytopenic Purpura 57 12 76 53 40
Immune Thrombocytopenic Purpura 57 12 59 73
Autoimmune Thrombocytopenic Purpura 12 53 15
Itp 57 53 59
Thrombocytopenia Due to Platelet Alloimmunization 73
Purpura, Thrombocytopenic, Idiopathic 44
Immune Thrombocytopenic Purpura; Itp 57
Thrombocytopenic Purpura Autoimmune 53
Purpura Thrombocytopenic Idiopathic 55
Primary Thrombocytopenic Purpura 12
Ideopath Thrombocytopenic Pur 12
Autoimmune Thrombocytopenia 73
Immune Thrombocytopenia 59
Idiopathic Purpura 12
Werlhof's Disease 12
Aitp 57

Characteristics:

Orphanet epidemiological data:

59
immune thrombocytopenic purpura
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: All ages;

OMIM:

57
Inheritance:
autosomal dominant form


HPO:

32
thrombocytopenic purpura, autoimmune:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 188030
Disease Ontology 12 DOID:8924
ICD10 33 D69.3
ICD9CM 35 287.31
MeSH 44 D016553
NCIt 50 C3446
Orphanet 59 ORPHA3002
MESH via Orphanet 45 D016553
UMLS via Orphanet 74 C0398650
ICD10 via Orphanet 34 D69.3
MedGen 42 C0398650

Summaries for Thrombocytopenic Purpura, Autoimmune

NIH Rare Diseases : 53 Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder characterized by too few platelets in the blood. This is because platelets are being destroyed by the immune system. Symptoms may include bruising, nosebleed or bleeding in the mouth, bleeding into the skin, and abnormally heavy menstruation. With treatment, the chance of remission (a symptom-free period) is good. Rarely, ITP may become a chronic ailment in adults and reappear, even after remission.

MalaCards based summary : Thrombocytopenic Purpura, Autoimmune, also known as idiopathic thrombocytopenic purpura, is related to thrombocytopenia due to platelet alloimmunization and purpura. An important gene associated with Thrombocytopenic Purpura, Autoimmune is FCGR2C (Fc Fragment Of IgG Receptor IIc (Gene/Pseudogene)), and among its related pathways/superpathways are TGF-Beta Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Dexamethasone and Amodiaquine have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and prostate, and related phenotypes are thrombocytopenia and thromboembolism

Disease Ontology : 12 A primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies.

OMIM : 57 Autoimmune thrombocytopenic purpura is characterized by a low platelet count, normal bone marrow, and the absence of other causes of thrombocytopenia. It is principally a disorder of increased platelet destruction mediated by autoantibodies to platelet-membrane antigens (George et al., 1994). (188030)

Wikipedia : 76 Immune thrombocytopenia (ITP) is a type of thrombocytopenic purpura defined as isolated low platelet... more...

Related Diseases for Thrombocytopenic Purpura, Autoimmune

Diseases related to Thrombocytopenic Purpura, Autoimmune via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia due to platelet alloimmunization 30.3 FCGR2C ITGA2B MPL SELP THPO
2 purpura 29.2 GP1BA ITGA2B ITGB3 MPL THPO
3 thrombocytopenia 27.1 GP1BA IL11 ITGA2B ITGB3 MPL THPO
4 immunodeficiency, common variable, 8, with autoimmunity 11.4
5 thrombocytopenia 3 10.7 MPL THPO
6 thrombocythemia 1 10.7 MPL THPO
7 amegakaryocytic thrombocytopenia, congenital 10.7 MPL THPO
8 dyskeratosis congenita, autosomal dominant 6 10.6 MPL THPO
9 splenomegaly 10.4 IFNA2 MPL
10 thrombocytopenia 1 10.4 SELP THPO
11 thrombocytopenia-absent radius syndrome 10.3 GP1BA MPL THPO
12 sticky platelet syndrome 10.3 GP6 ITGB3
13 acquired thrombocytopenia 10.3 IL11 THPO
14 arteritic anterior ischemic optic neuropathy 10.2 GP1BA ITGB3
15 sarcomatoid renal cell carcinoma 10.2 GATA3 IFNA2
16 clopidogrel resistance 10.2 ITGB3 SELP
17 anemia, autoimmune hemolytic 10.2
18 hemolytic anemia 10.2
19 myelofibrosis 10.1 IFNA2 MPL THPO
20 leukemia, chronic myeloid 10.0 IFNA2 MPL THPO
21 infective endocarditis 10.0 GP1BA ITGB3
22 coronary thrombosis 10.0 GP1BA GP6 ITGB3
23 bleeding disorder, platelet-type, 16 10.0 ITGA2B ITGB3
24 exanthema subitum 9.9 ITGA2B THPO
25 eosinophilic fasciitis 9.8
26 cartilage-hair hypoplasia 9.8
27 myasthenia gravis 9.8
28 gastric cancer 9.8
29 autoimmune hepatitis 9.8
30 evans' syndrome 9.8
31 fasciitis 9.8
32 myasthenia gravis congenital 9.8
33 thrombotic thrombocytopenic purpura, acquired 9.8
34 malignant skin fibrous histiocytoma 9.8 IFNA2 ITGA2B
35 carotid artery thrombosis 9.8 ITGA2B SELP
36 polycythemia vera 9.8 ITGB3 MPL SELP THPO
37 leukocyte adhesion deficiency, type iii 9.7 ITGA2B SELP
38 fetal and neonatal alloimmune thrombocytopenia 9.7 GP1BA ITGA2B ITGB3
39 autosomal dominant macrothrombocytopenia 9.7 GP1BA ITGA2B ITGB3
40 inherited blood coagulation disease 9.6 GP1BA ITGA2B ITGB3
41 intermediate coronary syndrome 9.6 ITGA2B SELP
42 malignant dermis tumor 9.6 IFNA2 ITGA2B
43 granulomatous hepatitis 9.5 IFNA2 ITGA2B
44 thrombocytosis 9.5 IL11 MPL SELP THPO
45 myelodysplastic syndrome 9.4 DNMT3B IL11 MPL THPO
46 autoimmune disease of blood 9.4 ITGA2B ITGB3 MPL THPO
47 hemorrhagic disease 9.4 ITGA2B ITGB3 MPL THPO
48 megakaryocytic leukemia 9.3 IL11 ITGA2B THPO
49 bernard-soulier syndrome 9.3 GP1BA ITGA2B ITGB3 THPO
50 hematologic cancer 9.2 IL11 MPL THPO

Graphical network of the top 20 diseases related to Thrombocytopenic Purpura, Autoimmune:



Diseases related to Thrombocytopenic Purpura, Autoimmune

Symptoms & Phenotypes for Thrombocytopenic Purpura, Autoimmune

Symptoms via clinical synopsis from OMIM:

57
Heme:
thrombocytopenia
bleeding diathesis

Lab:
platelet antibody


Clinical features from OMIM:

188030

Human phenotypes related to Thrombocytopenic Purpura, Autoimmune:

59 32 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thrombocytopenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001873
2 thromboembolism 59 32 hallmark (90%) Very frequent (99-80%) HP:0001907
3 petechiae 59 32 frequent (33%) Frequent (79-30%) HP:0000967
4 arterial thrombosis 59 32 frequent (33%) Frequent (79-30%) HP:0004420
5 gingival bleeding 59 32 occasional (7.5%) Occasional (29-5%) HP:0000225
6 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
7 bruising susceptibility 59 32 occasional (7.5%) Occasional (29-5%) HP:0000978
8 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
9 cerebral hemorrhage 59 32 very rare (1%) Very rare (<4-1%) HP:0001342
10 purpura 59 Frequent (79-30%)
11 abnormal bleeding 32 HP:0001892
12 platelet antibody positive 32 HP:0003454

MGI Mouse Phenotypes related to Thrombocytopenic Purpura, Autoimmune:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 DNMT3B GATA3 GP1BA GP6 ITGA2B ITGB3
2 immune system MP:0005387 9.28 DNMT3B GATA3 GP6 ITGA2B ITGB3 LRBA

Drugs & Therapeutics for Thrombocytopenic Purpura, Autoimmune

Drugs for Thrombocytopenic Purpura, Autoimmune (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 929)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
2
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
3
Artemether Approved Phase 4,Phase 3 71963-77-4 119380 68911
4
Artesunate Approved, Investigational Phase 4,Not Applicable 88495-63-0 6917864 5464098
5
Dihydroartemisinin Approved, Investigational Phase 4,Phase 3,Phase 2 71939-50-9 6918483
6
Lumefantrine Approved Phase 4,Phase 3 82186-77-4 6437380
7
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
8
Piperaquine Approved, Investigational Phase 4,Phase 3,Phase 2 4085-31-8 5079497
9
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
12
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757
13 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2 979-32-8
14
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
15
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
16
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
17
Polyestradiol phosphate Approved Phase 4,Phase 2 28014-46-2
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-14-0 4993
19
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2447-57-6 17134
20
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
21
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
22
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613
23
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
24
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
25
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
26
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
27
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
28
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
29
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
30
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
32
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
33
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
34
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
35
Hydroxychloroquine Approved Phase 4 118-42-3 3652
36
Dinoprostone Approved Phase 4 363-24-6 5280360
37
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
38
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
39
Ezetimibe Approved Phase 4 163222-33-1 150311
40
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79902-63-9 54454
41
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
42
Lopinavir Approved Phase 4 192725-17-0 92727
43
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
44
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
45
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
46
Rosiglitazone Approved, Investigational Phase 4,Phase 1,Not Applicable 122320-73-4 77999
47
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
48
Acetylcysteine Approved, Investigational Phase 4,Phase 3 616-91-1 12035
49
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
50
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969

Interventional clinical trials:

(show top 50) (show all 1514)
# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
3 Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols Unknown status NCT00742807 Phase 4 Low dose of alfentanil hydrochloride;Normal dose of alfentanil hydrochloride
4 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
5 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
6 Graz Study on the Risk of Atrial Fibrillation Unknown status NCT01461434 Phase 4
7 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
8 A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques Unknown status NCT02532309 Phase 4 Rosuvastatin (5mg,10mg,20mg);Rosuvastatin 5mg
9 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
10 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
11 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
12 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
13 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
14 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
15 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
16 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
17 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
18 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
19 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
20 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
21 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
22 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study Completed NCT00817843 Phase 4 Simvastatin;Simvastatin/Ezetimibe
23 Comparison of Rotating vs. Fixed Platform of the COLUMBUS Knee Prosthesis Completed NCT00822640 Phase 4
24 Treatment of Depression in Adults Completed NCT00073697 Phase 4 Escitalopram
25 Raltegravir Kaletra Pharmacokinetics Completed NCT00564772 Phase 4 Raltegravir, lopinavir, ritonavir
26 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4 Acular, Xibrom
27 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
28 A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID) Completed NCT01023724 Phase 4 Ketorolac Tromethamine 0.45%;Bromfenac 0.09%
29 Effect of Thiazolidinedione Treatment Vascular Risk Markers Completed NCT00571506 Phase 4 Rosiglitazone;Pioglitazone
30 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
31 Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion Completed NCT00188773 Phase 4 N-acetylcysteine, intralipid, heparin
32 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
33 Mechanism of Growth Hormone Effects on Adipose Tissue Completed NCT00453557 Phase 4 rhGH
34 "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM Completed NCT00402012 Phase 4 Pioglitazone
35 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients Completed NCT00347503 Phase 4 ketorolac 0.4%, bromfenac 0.09%
36 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
37 Oat Breakfast Satiety Study Completed NCT01372683 Phase 4
38 Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine Completed NCT00975325 Phase 4 Yohimbine;Yohimbine
39 Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy Completed NCT01170754 Phase 4 PEG-3350 and Gatorade;Golytely 4 liters
40 Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder Completed NCT00227968 Phase 4
41 Comparing Various Treatments for Achieving and Maintaining Remission of Depression Completed NCT00227955 Phase 4 Imipramine
42 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
43 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
44 Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent? Completed NCT01091714 Phase 4
45 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA) Completed NCT00094575 Phase 4
46 Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function Completed NCT00189085 Phase 4 simvastatin and ezetimibe
47 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed NCT00222820 Phase 4 escitalopram
48 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4 Desipramine
49 Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Completed NCT00751361 Phase 4
50 Cryoplasty CLIMB-registry Completed NCT00459888 Phase 4

Search NIH Clinical Center for Thrombocytopenic Purpura, Autoimmune

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: purpura, thrombocytopenic, idiopathic

Genetic Tests for Thrombocytopenic Purpura, Autoimmune

Anatomical Context for Thrombocytopenic Purpura, Autoimmune

MalaCards organs/tissues related to Thrombocytopenic Purpura, Autoimmune:

41
Lung, Heart, Prostate, Testes, Bone, Kidney, Liver

Publications for Thrombocytopenic Purpura, Autoimmune

Articles related to Thrombocytopenic Purpura, Autoimmune:

(show top 50) (show all 432)
# Title Authors Year
1
Idiopathic Thrombocytopenic Purpura Responsive to Surgery for Crohn's Disease. ( 29961815 )
2018
2
Case of atopic dermatitis concurrent with idiopathic thrombocytopenic purpura, whose serum thymus and activation-regulated chemokine level remained undetectable. ( 29399856 )
2018
3
No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab. ( 29400292 )
2018
4
Onset of type 1 diabetes mellitus and heparin-induced thrombocytopenia in a patient with Basedow's disease and idiopathic thrombocytopenic purpura: Novel combination as autoimmune polyglandular syndrome. ( 29905024 )
2018
5
Idiopathic thrombocytopenic purpura in a patient with IgG4-related disease. ( 29888414 )
2018
6
Systemic lupus erythematosus, following prodromal idiopathic thrombocytopenic purpura, presenting with skin lesions resembling malignant atrophic papulosis. ( 28691162 )
2017
7
Acquired amegakaryocytic thrombocytopenia previously diagnosed as idiopathic thrombocytopenic purpura in a patient with hepatitis C virus infection. ( 29085203 )
2017
8
Intravenous Immunoglobulin-Induced Profound Bradycardia in a Patient With Idiopathic Thrombocytopenic Purpura. ( 28930759 )
2017
9
Aortic Root Rupture during Transcatheter Aortic Valve Implantation in a Patient with Idiopathic Thrombocytopenic Purpura: Utility of Transesophageal Echocardiography in Early Detection and Description of a Semiconservative Surgical Management Approach. ( 28031654 )
2016
10
CD16 and CD32 Gene Polymorphisms May Contribute to Risk of Idiopathic Thrombocytopenic Purpura. ( 27315784 )
2016
11
A case of congenital prothrombin deficiency and idiopathic thrombocytopenic purpura in a pregnant female. ( 26886363 )
2016
12
Regulatory T Cells in Patients with Idiopathic Thrombocytopenic Purpura. ( 27211045 )
2016
13
Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura. ( 26984073 )
2016
14
Multiple cerebral infarctions in a patient with idiopathic thrombocytopenic purpura. ( 27648181 )
2016
15
Idiopathic Thrombocytopenic Purpura Masquerading Pediatric Systemic Lupus Erythematosus. ( 27057049 )
2016
16
Predictive Factors of Idiopathic Thrombocytopenic Purpura and Long-term Survival in Chinese Adults Undergoing Laparoscopic Splenectomy. ( 27749769 )
2016
17
Impact of serum immunoglobulins level and IL-18 promoter gene polymorphism among Egyptian patients with idiopathic thrombocytopenic purpura. ( 27600402 )
2016
18
Two cases of Vici syndrome associated with Idiopathic Thrombocytopenic Purpura (ITP) with a review of the literature. ( 26854214 )
2016
19
Dameshek W, Miller EB. The megakaryocytes in idiopathic thrombocytopenic purpura, a form of hypersplenism. 1946. ( 26744432 )
2016
20
Cytokine-induced killer cell therapy-associated idiopathic thrombocytopenic purpura: rare but noteworthy. ( 27485074 )
2016
21
Primary Splenic Angiosarcoma Presenting as Idiopathic Thrombocytopenic Purpura: A Case Report and Review of the Literature. ( 27651973 )
2016
22
Use of Romiplostim in Patients with Chronic Idiopathic Thrombocytopenic Purpura (cITP) During Peri-Operative Period. ( 25904300 )
2015
23
Successful prevention of exacerbation of thrombocytopenia in a pregnant patient with idiopathic thrombocytopenic purpura by anticoagulation treatment. ( 25884311 )
2015
24
A Case Report of an Elderly Woman With Thrombocytopenia and Bilateral Lung Infiltrates: A Rare Association Between Diffuse Alveolar Hemorrhage and Idiopathic Thrombocytopenic Purpura. ( 26683938 )
2015
25
Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children. ( 26214772 )
2015
26
Head trauma and intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. ( 26035504 )
2015
27
Relationships among HLA-DRB1 Alleles, Helicobacter pylori infection and idiopathic thrombocytopenic purpura in children. ( 26129806 )
2015
28
Editorial Comment to Resection of bulky chromophobe renal cell carcinoma resolved severe idiopathic thrombocytopenic purpura: A case report. ( 26394806 )
2015
29
Peliosis hepatis presenting with massive hepatomegaly in a patient with idiopathic thrombocytopenic purpura. ( 26770928 )
2015
30
Methorexate therapy in a patient with rheumatoid arthritis complicated by idiopathic thrombocytopenic purpura. ( 27708921 )
2015
31
Resection of bulky chromophobe renal cell carcinoma resolved severe idiopathic thrombocytopenic purpura: A case report. ( 26354444 )
2015
32
Dieulafoy lesion in the ascending colon presenting with gastrointestinal bleeding and severe anemia complicated by a coexisting severe resistant chronic idiopathic thrombocytopenic purpura. ( 25405040 )
2014
33
A case associated with comorbidities among cerebral infarction, idiopathic thrombocytopenic purpura, and triple x syndrome. ( 25035678 )
2014
34
Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). ( 24460857 )
2014
35
Mucous Membrane Pemphigoid with Immunoglobulin G Autoantibodies to the 120-kDa Ectodomain of Type XVII Collagen (BP180/Linear IgA Dermatosis Antigen) in a Patient with Idiopathic Thrombocytopenic Purpura. ( 25178495 )
2014
36
Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient. ( 23320868 )
2014
37
A case of refractory thrombocytopenia with 5q deletion: myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura. ( 25368823 )
2014
38
Can we predict neonatal thrombocytopenia in offspring of women with idiopathic thrombocytopenic purpura? ( 25548760 )
2014
39
Pulmonary hyalinizing granuloma associated with idiopathic thrombocytopenic purpura. ( 24744965 )
2014
40
Pregnancy outcome in patients with idiopathic thrombocytopenic purpura. ( 23852640 )
2014
41
Triad of Idiopathic Thrombocytopenic Purpura, Preeclampsia, and HELLP Syndrome in a Parturient: A Rare Confrontation to the Anesthetist. ( 25548684 )
2014
42
Rebalanced hemostasis in patients with idiopathic thrombocytopenic purpura. ( 24433238 )
2014
43
The authors' reply to Allen et al.: &amp;quot;A Comment on Boyers et al.: 'eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal'&amp;quot;. ( 23329596 )
2013
44
Idiopathic thrombocytopenic purpura during pregnancy. ( 23307463 )
2013
45
Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura. ( 23782272 )
2013
46
Refractory idiopathic thrombocytopenic purpura treated with immunoadsorption using tryptophan column. ( 23628355 )
2013
47
Evaluation of humoral immune function in patients with chronic idiopathic thrombocytopenic purpura. ( 23454778 )
2013
48
Anaesthesia for Caesarean Section of Pregnant Women with Idiopathic Thrombocytopenic Purpura. ( 27366365 )
2013
49
Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura. ( 24198982 )
2013
50
Renal transplantation in idiopathic thrombocytopenic purpura. ( 23816733 )
2013

Variations for Thrombocytopenic Purpura, Autoimmune

Copy number variations for Thrombocytopenic Purpura, Autoimmune from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21699 1 160500000 165500000 Copy number FCGR2C Idiopathic thrombocytopenic purpura
2 46119 10 77700000 82000000 Copy number BMPR1A Idiopathic thrombocytopenic purpura
3 121460 18 43500000 48200000 Copy number MADH4 Idiopathic thrombocytopenic purpura

Expression for Thrombocytopenic Purpura, Autoimmune

Search GEO for disease gene expression data for Thrombocytopenic Purpura, Autoimmune.

Pathways for Thrombocytopenic Purpura, Autoimmune

Pathways related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 IFNA2 IL11 ITGA2B ITGB3 MPL THPO
2
Show member pathways
12.69 GATA3 GP1BA GP6 IFNA2 ITGA2B ITGB3
3
Show member pathways
12.33 IFNA2 IL11 MPL THPO
4
Show member pathways
11.95 GP6 ITGB3 SELP
5
Show member pathways
11.85 GP1BA GP6 ITGA2B ITGB3
6 11.71 GP1BA GP6 ITGA2B ITGB3
7
Show member pathways
11.65 GP1BA ITGA2B ITGB3 MPL THPO
8 11.54 GP1BA IL11 ITGA2B ITGB3 THPO
9 11.29 GP6 ITGA2B ITGB3
10 11.23 GP1BA IFNA2 IL11 ITGA2B ITGB3 MPL
11 11.07 ITGA2B ITGB3
12 10.94 ITGA2B ITGB3
13 10.82 ITGA2B ITGB3
14 10.57 GP1BA GP6

GO Terms for Thrombocytopenic Purpura, Autoimmune

Cellular components related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 GP1BA GP6 ITGA2B ITGB3 MPL
2 integrin complex GO:0008305 9.16 ITGA2B ITGB3
3 platelet alpha granule membrane GO:0031092 8.8 ITGA2B ITGB3 SELP

Biological processes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.63 GP6 ITGB3 SELP
2 platelet degranulation GO:0002576 9.58 ITGA2B ITGB3 SELP
3 cytokine-mediated signaling pathway GO:0019221 9.55 GATA3 GP1BA IFNA2 IL11 MPL
4 platelet activation GO:0030168 9.54 GP1BA GP6 ITGB3
5 negative regulation of endothelial cell apoptotic process GO:2000352 9.43 GATA3 IL11
6 blood coagulation GO:0007596 9.35 GATA3 GP1BA GP6 IFNA2 ITGB3
7 positive regulation of leukocyte migration GO:0002687 9.32 ITGA2B SELP
8 thrombopoietin-mediated signaling pathway GO:0038163 9.26 MPL THPO
9 platelet aggregation GO:0070527 8.92 GP1BA ITGA2B ITGB3 MPL

Molecular functions related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 DNMT3B FCGR2C GATA3 GP1BA GP6 IFNA2
2 cytokine activity GO:0005125 9.13 IFNA2 IL11 THPO
3 extracellular matrix binding GO:0050840 8.62 ITGA2B ITGB3

Sources for Thrombocytopenic Purpura, Autoimmune

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....